COMMUNIQUÉS West-GlobeNewswire

Cytokinetics to Present at the Cantor Fitzgerald Global Healthcare Conference

26/09/2019 - 22:00

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK ) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate [...]

European Commission Approves Trogarzo®

26/09/2019 - 20:13

MONTREAL, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that Trogarzo ® (ibalizumab) was approved today by the European Commission. “The approval of [...]

La Commission européenne approuve Trogarzo(MD)

26/09/2019 - 20:13

MONTRÉAL, 26 sept. 2019 (GLOBE NEWSWIRE) -- Theratechnologies inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer que Trogarzo MD (ibalizumab) a été approuvée par la Commission européenne. « L’approbation de [...]

Resolute Onyx™ DES Meets Primary Endpoint in First-Ever Clinical Study Comparing Drug-Eluting Stents in High-Bleeding Risk (HBR) Patients with One-Month DAPT

26/09/2019 - 19:50

TCT19: First Results from Onyx ONE Global Study Also Show Superior Acute Performance and Build Upon Robust Clinical Evidence for Resolute Onyx with Shortened DAPT DUBLIN and SAN FRANCISCO, Sept. 26, 2019 (GLOBE NEWSWIRE [...]

Annual General Meeting in Oasmia Pharmaceutical AB on September 26, 2019

26/09/2019 - 19:00

This is an unofficial in-house translation of the Swedish original. In case of differences the Swedish version shall prevail. Today, September 26, 2019, Oasmia Pharmaceutical AB (publ) held its Annual General Meeting ( [...]

2019 Half-year consolidated results: Deinove’s progress coming to fruition

26/09/2019 - 18:30

2019 Half-year consolidated results: Deinove’s progress coming to fruition Launch of the Phase II trial testing DNV3837 for first-line treatment of moderate to severe Clostridioides difficile infections Communication by [...]

Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE

26/09/2019 - 18:30

Résultats semestriels 2019 : Matérialisation des avancements de DEINOVE Lancement de l’essai de Phase II testant DNV3837 en traitement de première ligne des infections gastrointestinales sévères à Clostridioides [...]

Constellation Pharmaceuticals to Present at Cantor Global Healthcare Conference

26/09/2019 - 18:00

CAMBRIDGE, Mass., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Constellation Pharmaceuticals , Inc. (Nasdaq: CNST), a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel [...]

Zynerba Pharmaceuticals to Present at the 2019 Cantor Global Healthcare Conference

26/09/2019 - 17:50

DEVON, Pa., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric [...]

Nicox : Rapport semestriel 2019

26/09/2019 - 17:45

Communiqué de presse Nicox : Rapport semestriel 2019 26 septembre 2019 Sophia Antipolis, France Le rapport financier semestriel au 30 juin 2019 de la société Nicox SA (Euronext Paris: FR0013018124, COX, éligible PEA-PME [...]

Inventiva receives FDA Fast Track designation for lead asset lanifibranor in NASH

26/09/2019 - 17:45

Designation is intended to facilitate the development and expedite the regulatory review of lanifibranor for the treatment of NASH Daix (France), September 26, 2019 – Inventiva (Euronext: IVA), a clinical-stage [...]

Inventiva obtient le statut « Fast Track » de la FDA pour son produit candidat phare, lanifibranor, dans la NASH

26/09/2019 - 17:45

Ce statut est destiné à faciliter le développement et à accélérer l’examen réglementaire de lanifibranor pour le traitement de la NASH Daix (France), le 26 septembre 2019 – Inventiva (Euronext : IVA), société [...]

Genmab Announces U.S. FDA Approval of DARZALEX® (daratumumab) in Combination with Bortezomib, Thalidomide and Dexamethasone for Frontline Multiple Myeloma

26/09/2019 - 17:43

Company Announcement DARZALEX (daratumumab) approved by U.S. FDA in combination with bortezomib, thalidomide (an immunomodulatory agent) and dexamethasone as treatment for patients newly diagnosed with multiple myeloma [...]

Disclosure of a transparency notification

26/09/2019 - 17:40

PRESS RELEASE : REGULATED INFORMATION 26 September 2019, 17:40 CEST Disclosure of a transparency notification Mechelen, Belgium, 26 September 2019 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative [...]

Clinical Validations for IV-Cell™ and HemeScreen™ Completed

26/09/2019 - 16:53

Orders expected from several major labs both domestically and internationally NEW HAVEN, Conn., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Specialty diagnostics company Precipio, Inc. ( NASDAQ: PRPO ), announced that as it [...]

Theratechnologies Included in the First TSX30 Ranking

26/09/2019 - 16:29

MONTREAL, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that it ranked 21 st on the first TSX30 ranking of top performers on the Toronto Stock Exchange. [...]

Theratechnologies se classe au palmarès TSX30

26/09/2019 - 16:29

MONTRÉAL, 26 sept. 2019 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) est heureuse d’annoncer qu’elle occupe la 21 e position du tout premier classement TSX30 des sociétés les plus [...]

Vaxart Announces Pricing of $8 Million Underwritten Public Offering

26/09/2019 - 16:20

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT), a clinical-stage biopharmaceutical company focused on the development of oral recombinant vaccines based on its proprietary [...]

Pressure BioSciences’ PCT Platform Featured in Multiple Presentations at Major International Science Conference

26/09/2019 - 15:29

Ten Presentations by Scientists from Seventeen Research Institutions Worldwide Highlight Novel Applications for PBI’s PCT Platform in Cancer Research and Diagnostics South Easton, MA, Sept. 26, 2019 (GLOBE NEWSWIRE) -- [...]